wyeth

  • Wyeth Receives Approval for Arthritis Drug

    Wyeth has received approval from the Japanese Ministry of Health, Labor and Welfare to add the indication of treating polyarticular Juvenile Idiopathic Arthritis (JIA) to “Enbrel 25mg for SC Injection,” (etanercept). The company also received…

    wyeth | 23 July 2009

  • Elan and Wyeth to Amend Bapineuzumab Phase III Protocols

    Elan Corporation and Wyeth will discontinue the highest of three dosing regimens, 2.0 mg/kg, in the two ongoing Phase III studies of bapineuzumab in patients with mild to moderate Alzheimer’s disease (AD) who do not carry the Apolipoprotein E4 (Ap…

    wyeth | 01 May 2009

  • Analysis suggest Wyeth's investigational compound BZA/CE comparable to placebo

    A retrospective analysis of Phase 3 two-year data presented at the annual meeting of the North American Menopause Society (NAMS) suggest that postmenopausal women treated with bazedoxifene/conjugated estrogens (BZA/CE) may experience incidence of bre…

    wyeth | 09 October 2008

  • Wyeth receives FDA approvable letter for Bazedoxifene

    Wyeth Pharmaceuticals announced the U.S. Food and Drug Administration (FDA) issued an approvable letter on May 21 for bazedoxifene, a selective estrogen receptor modulator, for the treatment of postmenopausal osteoporosis. In the letter, the FDA …

    wyeth | 27 May 2008

  • Wyeth Introduces the miniDAWN TREOS

    Wyeth Technology, the world leader in absolute macromolecular characterization instrumentation and software, introduces the miniDAWN TREOS Multi-Angle Light Scattering Detector, which has twice the signal to noise ratio and 100 times the dynamic rang…

    wyeth | 25 April 2006

  • Wyeth Enters into Research Partnership with GVK Biosciences

    US-based Wyeth Pharmaceuticals has signed a research agreement with one of India’s contract research organizations (CROs) GVK Biosciences located in Hyderabad. According to Frank Walsh, executive vice president and head of discovery research at …

    wyeth | 21 February 2006

  • Wyeth Enters into Research Partnership with GVK Biosciences

    US-based Wyeth Pharmaceuticals has signed a research agreement with one of India’s contract research organizations (CROs) GVK Biosciences, located in Hyderabad. According to Frank Walsh, executive vice president and head of discovery research at…

    wyeth | 01 February 2006